Mark L. Pacala Buys 90,562 Shares of The Oncology Institute, Inc. (NASDAQ:TOI) Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Mark L. Pacala bought 90,562 shares of the firm’s stock in a transaction on Wednesday, March 26th. The shares were bought at an average cost of $1.04 per share, for a total transaction of $94,184.48. Following the purchase, the director now owns 224,971 shares of the company’s stock, valued at approximately $233,969.84. The trade was a 67.38 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Oncology Institute Price Performance

TOI traded up $0.03 on Friday, reaching $1.14. The stock had a trading volume of 502,477 shares, compared to its average volume of 699,326. The firm has a 50-day moving average of $0.85 and a 200-day moving average of $0.47. The Oncology Institute, Inc. has a fifty-two week low of $0.13 and a fifty-two week high of $1.78. The company has a market capitalization of $86.14 million, a price-to-earnings ratio of -1.46 and a beta of 0.41. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 5.91.

Oncology Institute (NASDAQ:TOI) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). Oncology Institute had a negative net margin of 17.63% and a negative return on equity of 186.83%. The business had revenue of $100.27 million during the quarter, compared to the consensus estimate of $109.15 million.

Hedge Funds Weigh In On Oncology Institute

A number of hedge funds have recently modified their holdings of TOI. Renaissance Technologies LLC lifted its holdings in Oncology Institute by 7.1% during the 4th quarter. Renaissance Technologies LLC now owns 182,000 shares of the company’s stock worth $56,000 after buying an additional 12,000 shares during the period. HighTower Advisors LLC lifted its stake in shares of Oncology Institute by 190.8% in the third quarter. HighTower Advisors LLC now owns 81,362 shares of the company’s stock worth $27,000 after acquiring an additional 53,382 shares during the period. Jane Street Group LLC lifted its stake in shares of Oncology Institute by 613.6% in the fourth quarter. Jane Street Group LLC now owns 127,659 shares of the company’s stock worth $39,000 after acquiring an additional 109,769 shares during the period. Virtu Financial LLC acquired a new stake in Oncology Institute during the 4th quarter valued at approximately $41,000. Finally, Tiff Advisory Services LLC raised its holdings in Oncology Institute by 13.2% during the 4th quarter. Tiff Advisory Services LLC now owns 2,979,141 shares of the company’s stock worth $921,000 after purchasing an additional 346,256 shares during the last quarter. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.